… long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of … RNA therapies.” But what about gene therapy, isn’t that an option? “There are several reasons to choose RNA therapy over … Can we learn more about our molecules, and does it help to optimize our protocols? Those are just some of the questions …
… with Lilly and Company . The partnership focuses on developing potential medicines using our Axiomer ® RNA … is to progress new medicine technology towards clinical development and, ultimately, to patients via … into diseases of which there are little to no treatment options. In our vision partnerships are true catalyst for the …
… collaboration with Lilly. The partnership focuses on developing potential medicines using our Axiomer RNA editing … beginning, ProQR has been focused on RNA technologies to develop medicines for people and families with high unmet … additional targets, along with an option for Lilly to opt in for more. Lilly is a leader in RNA therapeutics, and …
… data into standardized, AI-ready datasets Automate and optimize data flows to reduce manual steps and improve … using scripting and containerized tools (e.g., Docker) Develop, train, and evaluate AI models using JAX or PyTorch … initiatives, including FAIR-compliant schema development, metadata standards, and integration with …
… and Cambridge, Massachusetts, USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet … activities include: Prepare mechanistic minimal PBPK and/ (population) PKPD M&S-based strategies to support discovery … generate predictive (human) exposure profiles and to guide optimal dosing strategies and ensure therapeutic efficacy and …
… approaches to drive scientific and operational excellence. Develop and determine optimal methods for new assignments by … we are true believers of the value of a workforce in which people from diverse backgrounds are encouraged to develop … and professionally. We believe that happy and energized people, working well together in an environment in which they …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
… as well as creating de novo mutations. Presented at OPT Congress 2023 by Gerard Platenburg - ProQR Therapeutics … background in RNA modulation and orphan drug discovery and development and is currently in charge of our Innovation …
